


Glutaminase-IN-1

Cat. No.:	HY-114334		
CAS No.:	2247127-79-1		
Molecular Formula:	C ₂₆ H ₂₄ F ₃ N ₇ O ₃ Se		
Molecular Weight:	618		
Target:	Glutaminase		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (40.45 mM); ultrasonic and warming and heat to 60°C
 H₂O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent		1 mg	5 mg	10 mg
	Concentration	Mass			
1 mM			1.6181 mL	8.0906 mL	16.1812 mL
5 mM			0.3236 mL	1.6181 mL	3.2362 mL
10 mM			0.1618 mL	0.8091 mL	1.6181 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.08 mg/mL (3.37 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 1.44 mg/mL (2.33 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Glutaminase-IN-1 (CB839 derivative), a CB839 derivative, is an allosteric inhibitor of 1,3,4-selenadiazole-containing kidney-type glutaminase (KGA), with an IC₅₀ of 1 nM. Glutaminase-IN-1 (CB839 derivative) shows improved cellular uptake and antitumor activity.

IC₅₀ & Target

IC₅₀: 1 nM (KGA)^[1].

In Vitro

Glutaminase-IN-1 (CPD20), a CB839 derivative, is an allosteric inhibitor of 1,3,4-selenadiazole-containing kidney-type glutaminase (KGA), with an IC₅₀ of 1 nM. Glutaminase-IN-1 shows improved cellular uptake and antitumor activity. The IC₅₀ values of Glutaminase-IN-1 are 17 nM, 6.78 μM, 19 nM and 9 nM in A549, H2, Caki-1 and HCT116 cell lines, respectively.

Glutaminase-IN-1 has better KGA inhibitory activity than the corresponding BPTES and CB839^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Glutaminase-IN-1(10 mg/kg, s.c.) reduced the size and weight of the HCT116 tumor, and statistical analysis showed that the 40% reduction in tumor weight by CPD20 is statistically significant. Glutaminase-IN-1 could statistically significantly prolong the survival of H22-bearing mice^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Chen Z, et al. Novel 1,3,4-Selenadiazole Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity. J Med Chem. 2018 Dec 13.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA